序号 | 受理号 | 药品名称 | 药品类型 | 申请类型 | 注册分类 | 企业名称 | 承办日期 |
1 | JYHS2400036 | 盐酸左西替利嗪口服溶液 | 化药 | 进口 | 5.2 | BRIGHT FUTURE PHARMACEUTICAL LABORATORIES LIMITED;BRIGHT FUTURE PHARMACEUTICALS FACTORY;/; | 2024/7/13 |
2 | JXSS2400056 | 伊匹木单抗注射液 | 治疗用生物制品 | 进口 | 2.2 | Bristol-Myers Squibb Pharma EEIG;Bristol-Myers Squibb Holdings Pharma, Ltd., Liability Company;Bristol-Myers Squibb (China) Investment Co., Ltd.; | 2024/7/13 |
3 | JXSS2400055 | 伊匹木单抗注射液 | 治疗用生物制品 | 进口 | 2.2 | Bristol-Myers Squibb Pharma EEIG;Bristol-Myers Squibb Holdings Pharma, Ltd., Liability Company;Bristol-Myers Squibb (China) Investment Co., Ltd.; | 2024/7/13 |
4 | JXHL2400180 | TAK-861片 | 化药 | 进口 | 1 | Takeda Development Center Americas,Inc.;/; | 2024/7/12 |
5 | JXHL2400179 | TAK-861片 | 化药 | 进口 | 1 | Takeda Development Center Americas,Inc.;/; | 2024/7/12 |
6 | JXHL2400178 | TAK-861片 | 化药 | 进口 | 1 | Takeda Development Center Americas,Inc.;/; | 2024/7/12 |
7 | JXHL2400177 | TAK-861片 | 化药 | 进口 | 1 | Takeda Development Center Americas,Inc.;/; | 2024/7/12 |
8 | JXSL2400123 | 度普利尤单抗注射液 | 治疗用生物制品 | 进口 | 3.1 | Sanofi Winthrop Industrie;Sanofi (China) Investment Co., Ltd.; | 2024/7/12 |
9 | JXSL2400122 | 艾加莫德α注射液 | 治疗用生物制品 | 进口 | 2.2 | argenx BV;Zai Lab (Shanghai) Co., Ltd.; | 2024/7/12 |
10 | JXSL2400121 | MK-3475A注射液 | 治疗用生物制品 | 进口 | 1 | Merck Sharp & Dohme LLC;MSD R&D (China) Co. Ltd; | 2024/7/12 |
11 | JXHL2400176 | Bomedemstat胶囊 | 化药 | 进口 | 1 | Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.;MSD R&D (China) Co. Ltd.; | 2024/7/12 |
12 | JXHL2400175 | Bomedemstat胶囊 | 化药 | 进口 | 1 | Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.;MSD R&D (China) Co. Ltd.; | 2024/7/12 |
13 | JXHL2400174 | Bomedemstat胶囊 | 化药 | 进口 | 1 | Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.;MSD R&D (China) Co. Ltd.; | 2024/7/12 |
14 | JXHL2400173 | Bomedemstat胶囊 | 化药 | 进口 | 1 | Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.;MSD R&D (China) Co. Ltd.; | 2024/7/12 |
15 | JXHL2400172 | 罗氟司特乳膏 | 化药 | 进口 | 2.4 | Arcutis Biotherapeutics INC;无; | 2024/7/12 |
16 | JXHL2400171 | BI 1839100 片 | 化药 | 进口 | 1 | Boehringer Ingelheim International GmbH;Boehringer Ingelheim (China) Investment Co.,Ltd.; | 2024/7/12 |
17 | JXSL2400120 | CSL300 (Clazakizumab) | 治疗用生物制品 | 进口 | 1 | CSL Behring LLC;Fortrea Pharmaceutical Research and Development (Beijing) Co., Ltd.; | 2024/7/10 |
18 | JXHL2400170 | Elacestrant片 | 化药 | 进口 | 5.1 | Stemline Therapeutics, Inc.;SciClone Pharmaceuticals (China) Co., Ltd.; | 2024/7/10 |
19 | JXHL2400169 | Elacestrant片 | 化药 | 进口 | 5.1 | Stemline Therapeutics, Inc.;SciClone Pharmaceuticals (China) Co., Ltd.; | 2024/7/10 |
20 | JXHL2400168 | BAY 2862789片 | 化药 | 进口 | 1 | Bayer AG;Bayer Healthcare Company Ltd.; | 2024/7/9 |
21 | JXHL2400167 | BAY 2862789片 | 化药 | 进口 | 1 | Bayer AG;Bayer Healthcare Company Ltd.; | 2024/7/9 |
22 | JXHL2400166 | PF-06821497片 | 化药 | 进口 | 1 | Pfizer Inc. fizer Investment Co., Ltd.; | 2024/7/8 |
23 | JXHL2400165 | PF-06821497片 | 化药 | 进口 | 1 | Pfizer Inc. fizer Investment Co., Ltd.; | 2024/7/8 |